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Abstract
Background: Treatment of pancreatic metastases (PM) from renal cell carcinoma (RCC) is still an issue between
surgeons and oncologists, in the era of target-therapy.
Methods: Data from 26 patients undergoing resection of PM and extra-PM from RCC, with R0 intention were
retrospectively analysed. No one received adjuvant chemotherapy. Patients were divided into two groups; Group A
comprehends 14 patients who developed synchronous (5) or methacronous (9) extra-PM. Group B comprehends 12
patients that developed PM only.
Results: No intraoperative mortality was recorded. Complications occurred in 14 patients (53.8%), all but 2 (7.26%)
were graded I and II according to Clavien-Dindo classification.
Recurrences occurred in 8 patients (30.8%), of whom, 5 (62.5%) were submitted for further resections in other sites.
Three-, five- and ten-year observed overall survival were respectively 88,5% [95%CI: 0,56 – 1,33], 76,9% [95%CI: 0,47 –
1,19] and 50% [95%CI: 0,20 – 1,03]. Disease-free survival was 65,4% [95%CI: 0,38 – 1,05], at 3 years, 57,7% [95%CI 0,
323 – 0,952] at 5 years and 42,9% [95%CI 0,157 – 0,933], at 10 years. QoL analysis, through WHOQOL-BREF
questionnaire, assessed at last available follow up revealed a mean score of 75,9 ± 11,6 on 100 points.
Conclusion: Despite no significant differences in survival between patients affected by Pancreatic or Extra-
Pancreatic metastases, PM patients seems to show better outcome when managed surgically. mRCC patients,
eligible for radical metastasectomy, tend to have long survival rates, reduced recurrence rates and good QoL.
Study registration: This paper was registered retrospectively in ClinicalTrials.gov with Identification number:
NCT03670992.
Keywords: Renal cell carcinoma, RCC, Pancreatic resection, Robotic surgery, Pancreatic metastases, Quality of Life;
cost-effectiveness.
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Background
Metastatic lesions in pancreas are extremely rare, ac-
counting for less than 5% of pancreatic malignancies di-
agnosed in living patients. Pancreatic metastases are
found more frequently at autopsy, being identified in up
to 15% of patients with malignant disease. While resec-
tion of metastatic lesions in liver and lung has been well
described and is generally accepted to improve survival,
the optimal management of pancreatic metastases is not
yet well accepted and there are still issues among clini-
cians [1]. Synchronous metastases from RCC occur in
25–30% and metachronous metastases in about 40% of
patients. Biology of metastatic RCC is heterogeneous.
Recurrences may present within 1 year from nephrec-
tomy with rapid progression of disease, or in some other
cases, tumour-free intervals of more than 20 years may
be observed with a slow growth pattern, especially for
pancreatic metastases [2]. Advancements in technology
and surgical techniques have reduced operative risk in
pancreatic surgery and therefore, allowed a more aggres-
sive approach in patients with solitary PM from RCC.
Pancreatic surgery in this clinical setting has already
proved satisfactory results [1–4]. Controversies still exist
regarding indications to surgical resection of metachro-
nous and/or synchronous pancreatic multiple metastases
and extra-PM from RCC [5–7]. Attention has been paid
mainly to overall survival and disease-free survival, QoL
after different forms of treatment has not been well ana-
lysed. We report cases of twenty-six consecutive patients
who underwent extended pancreatic resections for me-
tastases from clear cell RCC in order to achieve R0 re-
section. Patients with history of intra- and extra-
abdominal metastases, either in first presentation or dur-
ing follow-up, were enrolled in our study. In case
complete surgical resection of pancreatic and/or extra
pancreatic metastases was unachievable chemotherapy
was indicated. To our knowledge, this is the first paper
that gives special attention to patients’ QoL after surgery
for clear cell carcinoma, in a such long follow-up period.
Methods
Retrospective data was analysed from 26 patients sub-
mitted to pancreatic resection between August 2002 and
November 2015. Inclusion criteria were: single or mul-
tiple pancreatic or extra pancreatic metastases from clear
cell carcinoma (Table 1) and treatment non-associated
with adjuvant chemotherapy. Patients that already re-
ceived a previous pancreatic resection were also in-
cluded. Data in this manuscript has been reported in
line with the PROCESS criteria [8].
Different kind of surgical approaches were taken into
account in this study: duodenal-pancreatectomy, total-
pancreatectomy and distal-pancreatectomy associated or
not with other metastatic site resections. Surgery was
performed either with classical open approach or mod-
ern robotic approach, using the robot Da Vinci® Si
model. Aim of surgical interventions were to remove all
metastases in association to radical lymphadenectomy
thus to achieve R0 resection. Patients enrolled to cytore-
ductive surgery were excluded from this study and
treated with adjuvant chemotherapy [5]. All postopera-
tive events occurring within 90 days of surgery were con-
sidered. Postoperative complications were graded
according to Clavien-Dindo classification. Patients were
followed-up 3months after discharge and every 6
months thereafter. Patients had blood chemistries and
CT scans at least every year. MRI and bone scan were
used in case of inconclusive CT-scan, in order to evalu-
ate eventual liver, head and bone recurrences [5].
A database was used to record all patients’ data. Re-
sults were analysed in terms of Operative Mortality and
Morbidity, Overall Survival, Disease-Free Survival and
Quality of Life. Protocols approbation by the bioethical
review committee was waived since the retrospective na-
ture of the study and meet the guidelines of our
institutions.
Patients were divided into two groups; Group A com-
prehends 14 patients who developed synchronous (5 re-
cipients) or methacronous (9 recipients) extra-PM. Group
B comprehends 12 patients that developed PM only.
Present QoL was measured through WHOQOL-BREF
questionnaire [9] administered at last follow-up to the
19 patients still alive.
Retrospective QoL in past years was estimated through
combination of different parameters and by questionnaires
retrospectively fulfilled and based on patients’ recollection
at one, three, five and ten years after surgery: Karnofsky
performance scale, Activity of Daily Living scale (ADL)
[10], Instrumental Activity of Daily Living scale (IADL)
[11], and Geriatric Depression Scale (GDS) [12].
Nutritional status was measured by monitoring in clin-
ical records weight loss through BMI, by serum albumin
and haemoglobin levels at one, three, five and ten years
after surgery: Hb > 12,5 g/dl one point, serum albumin >
2 g/dl one point, and BMI > 19,5 Kg/m^2 one point.
Score 0–3.
Points were assigned through specific questionnaires
to Karnofsky (Score 0–100), IADL (Score 0–8), ADL
(Score 0–6) [10, 11].
As for ADL a score of 6 is considered as conserved
daily activity; 4–5 as moderate impairment; 2–3 as mild
impairment and 0–1 as severe impairment [10].
IADL measures impairment in instrumental activity, a
score of 8 is considered a conserved instrumental activ-
ity, 4–7 as moderate impairment, 2–4 as mild impair-
ment and 0–1 as severe impairment [11].
Presence or absence of depression was also considered
and evaluated through Geriatric Depression Scale (GDS-
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15): depression cut-off was set at 5 points of the scale
considering a score of 0–4 as non-depression; 5–9 as
mild depression and 10–15 as severe depression [12].
QoL was defined by combination of these parameters
as: excellent, good, fair, poor or very poor (Table 4).
Data was analysed via Chi-square test, as well as Mann-
Whitney test for parametrical and non-parametrical
values. Overall survival and disease-free survival were de-
scribed by Kaplan-Meier analysis. A log-rank test was used
to compare continuous variables and was expressed by
survival curves. Statistical significance was set at p ≤ 0,05.
Results
Twenty-six patients were submitted to nephrectomy for
RCC, PM appeared in follow-up after median 13 years
after primary tumour removal [range 2–35 years], except
in one case where simultaneous resection of bilateral
renal cancer and distal-pancreatectomy for metastases
was performed. Eight patients had a single pancreatic
metastasis, six of which greater than 2 cm in diameter.-
Eighteen patients had multiple pancreatic metastases, 10
of which greater than 2 cm in diameter.
Table 1 Patient's characteristics
Legend: Patients data and charateristics at time of nephrectomy and pancreatectomy.
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Five patients underwent previous resection of lung
metastases associated with liver metastases after neph-
rectomy (Table 1). Five patients, at time of pancreatic re-
section, had infiltration of one or more neighbouring
organs. Six patients had haematogenous metastases
(Table 1).
Overall, fourteen patients (53,8%) had previous or syn-
chronous resected extra-PM. Patients were considered
eligible for pancreatic resection by assessing ASA-score
[13], Charlson’s age-adjusted comorbidity index [14] and
the Memorial Sloan-Kettering Cancer Center risk score
[15] that were used to stratify the population based on
comorbidities and risk factors (Table 1).
Open surgery was performed in 22 patients; robotic
surgery was performed in 4. Conversion rate robotic to
open surgery was 0%. Complete resection was achieved
in all cases, either in pancreatic and extra-pancreatic
metastases, Table 2 describes the type of operations per-
formed. Complete data on resected lymph nodes were
available for 22 of the 26 patients. An average of 28
lymph nodes were resected. There was no difference be-
tween the average number of lymph nodes removed in
the 4 patients who had robotic surgery (mean of 26
lymph nodes per patient) and the 18 who had open sur-
gery (mean of 28 lymph nodes per patient). Out of the
659 lymph nodes analysed, only 5 nodes (0.7%) in 3 pa-
tients had cancer involvement.
Total pancreatectomy (TP) was performed in 13 pa-
tients; one underwent total pancreatectomy for recurrent
pancreatic (uncus) metastases treated by left pancreatic
resection 16 years earlier.
Distal pancreatectomy (DP) was performed in 5 pa-
tients and pancreaticoduodenectomy (PD) in the
remaining 8 patients. Spleen-preserving DP was per-
formed in 2 of the 5 patients. The pylorus was spared in
17 of 21 patients who underwent TP or PD (81%). About
the four robotic surgery procedures, 2 were PD, one was
TP and one was DP. One patient underwent synchron-
ous jejunum resection for a jejunal mass that revealed to
be a GIST (Table 2). There was no operative mortality
(within 90 days). Complications occurred in 14 patients
(53.8%), all but two were grade I or grade II according to
Clavien-Dindo classification and resolved rapidly.
One patient required re-laparotomy for intestinal
bleeding, the other one had acute respiratory distress
syndrome. Twelve patients with regular postoperative
period left the hospital at an average of 14 days from the
operation. Patients that underwent robotic surgery left
the hospital 15,16, 23 and 30 days after surgery.
Hospitalization was more than 21 days in 7 patients
due to pancreatic fistula (3 patients had biochemical
leak; 2 Grade B, 0 Grade C) [16] and/or for the occur-
rence of delayed gastric emptying (2 patients Grade A; 2
Grade B; 2 Grade C) [17].
No patients were lost during follow-up. Follow-up
ranged from 60 to 161 months (mean 104months).
During follow-up, metastases, in distant sites from
resected areas, recurred in 12 patients (46,2%) at an
average of 34 months from pancreatic resection (range
15–70months); 5 patients were suitable for a further re-
section. (Table 3).
Three cases (25%) came from the group with isolated
PM and 5 cases (36%) from the group with extra-PM.
Three-, five- and ten-year observed overall survival were
respectively 88,5% [95%CI: 0,56 – 1,33], 76,9% [95%CI: 0,
47 – 1,19] and 50% [95%CI: 0,20 – 1,03]. (Fig. 1).
Disease-free survival was 65,4% [95%CI: 0,38 – 1,05],
at 3 years, 57,7% [95%CI 0,323 – 0,952] at 5 years and
42,9% [95%CI 0,157 – 0,933], at 10 years. (Fig. 2).
No specific risk factor influenced survival.
In Group A mean OS was 89,1 months ±52,4 SD
[Range 4–162], mean DFS was 59,1 months ±52,9 SD
[Range 4–162].
In Group B mean OS was 77,8 months ±24,5 SD
[Range 23–141], mean DFS was 70,9 months ±31,1 SD
[Range 23–141]. Mann-Whitney test revealed no statisti-
cally significant difference between the two groups either
in OS and DFS (pOS = 0,490 and pDFS = 0,06).
Table 2 Type of Surgery
TYPE OF SURGERY
N.
Single PM 8a
PD 5
DP + Liver resection + Portal vein resection and Thrombectomy 1
DP +Wedge resection contralateral kidney 1
TP + Resection and reconstruction mesenteric vein 1
Multiple PM 18a
TP 7
TP + Liver resection 1
TP + Injection alcohol liver meta- stases 1
TP + Contralateral nephrectomy
+ Adrenalectomy
1
TP + Right colon resection 1
TP + Portal vein resection + Right colon resection 1
PD 2
PD + Jejunal resection 1
DP 2
DP + Contralateral nephrectomy 1
DP + Nephrectomy + Contralateral wedge nephrectomy 1
PD Pancreatic Duodenectomy DP Distal Pancreatectomy
TP Total Pancreatectomy
a Number of patients
Legend: Practiced surgical resections
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Table 3 Patient's outcome
Legend: Patients’ outcome after surgery
Fig. 1 Overall Survival representation of PM group vs extra-PM group
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Prevalence of recurrent metastatic disease (57,1% vs
33,3% [RR: 1,71; 95%CI: 0,459 – 7,7]) and tumour-
related deaths (35,7% vs 16,7% [RR: 2,14; 95%CI: 0,351 –
22,5]) were higher in Group A, however no statistically
significant difference was found in both cases (pRMD = 0,
149 and pTRD = 0,099 respectively). Table 3 describes the
status of the 26 patients at the end of the study period.
As for QoL analysis WHOQOL-BREF questionnaire
was administered to 19 patients still alive, overall mean
score was 75,9 on 100 points [± 11,6], dominion-related
analysis is showed in Table 4.
As for retrospective analysis 25 patients were alive one
year after surgery, 18 were alive at three years, 13 at five
years and 5 at ten years after surgery. Results of QoL
analysis are displayed in Table 4.
All patients submitted to TP had pancreatic exocrine
enzyme replacement therapy. Only two patients suffered
from steatorrhea and remained respectively five and ten
kilos below their preoperative weight, but blood chemis-
try did not show any evidence of malnutrition.
Three patients who had TP experienced episodes of
hypoglycaemia in the first year after surgery, this was
easily corrected without hospitalization.
Discussion
Despite early diagnosis and treatment, one-third of pa-
tients suffering from clear cell RCC developed local or
distant metastases [18].
Isolated PM from RCC are rare. Several reviews have re-
ported satisfactory results after RCC’s PM excision [1–4].
Adler et al [1] reviewed 18 case-series: pancreatic
metastases were observed mostly from RCC (62%); one
and five-years survival rates were 86 and 50%respectively.
All of them showed that excision of metastases from RCC
had better OS, however extra PM were associated with
poorer survival, not in line with our results. Hypothetically
this difference is due to further resections that received
our patients.
Surgical approach in metastatic disease is now an inte-
gral part of a multidisciplinary oncological therapy, good
results have been reported after an aggressive removal of
synchronous or methacronous metastases [19]. A
complete resection of the tumour can be followed by un-
expected long-term survival [1–4].
RCC is often associated with Von Hippel-Lindau
(VHL) pathway mutation, which neutralizes the action
of several hypoxia inducible factors (HIFs). Once active,
HIFs lead to Vascular Endothelial Growth Factor
(VEGF) activation that stimulates cell growth, vessel for-
mation and leads to tumour aggressiveness. Recently, in
several RCC was also shown an mTOR mutation that
would boost cell growth and, therefore malignant trans-
formation [20].
Target therapy for mRCC has been consistently devel-
oped in recent years, specific inhibitors of VEGF path-
way, mTOR pathway and PD-1/PD-L1 showed the most
consistent results. More than 11 molecules are available
for mRCC treatment in first, second and consequent line
protocols [21, 22]. (Table 5). Unexpected outcomes in
terms of Objective Response were shown by latest inves-
tigated molecule combinations such as Nivolumab/Ipili-
mumab and Atezolizumab/Bevacizumab (Objective
Fig. 2 Disease free survival after surgery of PM group vs extra-PM group
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Response > 30%, but Complete Response < 10% and
mean PFS of 13,1 and 10,4 months respectively) [22].
Many patients develop adverse effects that may be ex-
tremely debilitating (G3/G4 side effects). Intolerance to
target therapy leads therefore to dose-reduction or therapy
suspension, exposing recipients to disease progression’s
risk [22]. Dose Reduction is needed in 40–50% of patients,
Therapy Discontinuation in 20–25% and Treatment-
Associated deaths are rare [22].
Most common adverse effects are: Hypertension, Fa-
tigue, Mucositis, Diarrhoea, Neutropenia and Lympho-
penia. Nivolumab and Ipilimumab are associated with
immune mediated adverse effects in 80% of recipients
[22]. For all these reasons, patients treated with target-
therapy shall be followed-up very carefully, and thera-
peuthical adjustments shall be done according to indi-
vidual patient’s response, that may be variable and
unpredictable.
In mRCC, as this manuscript confirms, surgery re-
mains an extremely valid option, although it suffers from
an obvious selection bias, patients eligible to radical re-
section have longer DFS and reduced recurrence rate [1,
23, 24]. Robotic and Laparoscopic metastasectomy adds
the possibility of a less traumatic surgical approach and
Table 4 Quality of Life
Legend: WHOQOL-BREF assessment, quality of life retrospective evaluation scale and results
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widens surgical indications to patients previously consid-
ered unfit for open surgery [1, 7]. Moreover, radical sur-
gery aims at complete removal of the malignancy while
target therapy aims at controlling disease in a chronicised
state. However, surgical resection of PMs may not always
be the best treatment for RCC patients. Chemotherapy shall
be preferred to pancreatic resection in stage IV RCC if
complete resection is unachievable.
Surgery can also be cost-effective vs the most recent
tyrosine-kinase inhibitor molecules that in a chronic
therapy requires $ 20.000 and more per patient-year [25]
vs a median of $ 40.000 per patient for surgery [26].
In our groups of patients we were not able to find sig-
nificant differences in survival or disease recurrence
among the two groups, however it is possible to deduce
that in wider casuistic this may be possible, particularly
in DFS and tumour recurrence in patients with only
pancreatic metastases. Near-significant p values were
found in comparing DFS (p = 0,06) and Tumour Related
Deaths (p = 0,099) with better outcome for patients in
Group B, therefore it is possible to consider patients
with only Pancreatic Metastases from RCC, a long-
surviving, less-progressing Group.
As for QoL analysis, WHOQOL-BREF questionnaire
was administered to all patients alive at their last follow
up, showed a mean score higher than 75 on 100, which
is surprisingly high for metastatic patients.
QoL in past years might only be estimated retrospect-
ively, in order to achieve this, we retained that
WHOQOL-BREF was subject of too many biases, there-
fore we tried to focus on more objective parameters that
could be easily recollected by patients although much
time passed. In this retrospective research we aimed at
focusing either on general physical performance
evaluated by Karnofsky scale; patient’s ability to fulfil
personal needs and to use daily instruments assessed
through ADL and IADL scale; nutritional and psycho-
logical status. All these parameters are combined in a
qualitative evaluation from very poor to excellent since
quality of life is a multidimensional concept that in-
cludes one’s evaluation of well-being and functioning
across physical, psychological, social, and sexual do-
mains, with some conceptualizations including spiritual
well-being [27].
In order to better evaluate patient’s QoL in surgery we
decided to take some parameters from Comprehensive
Geriatric Assessment (CGA) used in clinical oncology to
assess patient’s QoL and fitness to chemotherapy [28],
these parameters were chosen due to the experience ma-
tured in treating geriatric patients in context of our geri-
atric unit and with collaboration of the Italian Geriatric
Oncologic Group (GOGI).
Quality of life is a critical outcome in clinical trials
and a significant predictor of treatment response. In
the existent PM’s surgical treatment studies, it is
rarely or limitedly taken into account. Instead, this is
one of few papers where QoL is carefully investi-
gated. In spite of the small number of our recipients,
many of them reported a good QoL, moreover, some
report an active and sporty life for several years after
surgery. Therefore, considering treatment for PM
from RCC, surgery shall be preferred, especially in
selected patients, anytime complete resection of RCC
metastases is achievable either pancreatic and extra-
pancreatic sites. Clear cell RCC is one the rare ma-
lignancies where surgery may achieve astonishing
long DFS and OS with important QoL benefit.
(Figs. 1 and 2).
Table 5 Target therapy for mRCC
TARGET THERAPY FOR mRCC – SCHEMES & RESULTS
Scheme/Drug Line of Treatment Molecular Target Mean PFS (Months) Mean OS(Months)
Sunitinib1,2 First mTKI 11 26,4
Temsirolimus1 First mTOR 1,9 10,9
Pazopanib1 First mTKI 11,8 22,9
Sorafenib1 Second mTKI 5,5 17,8
Bevacizumab + IFNα1 Second VEGF-A 8,5 18,3
Axitinib1 Second mTKI 6,7 20,1
Everolimus1 Second mTOR 4 14,8
Nivolumab1 Second PD-1 4,6 25
Cabozatinib1,2 Second mTKI 7,4 21,4
Lenvatinb + Everolimus1 Second mTKI/mTOR 14,6 NR
Nivolumab + Ipilimumab2 Second PD-1/PD-L1 12,6 NR
Atezolizumab + Bevacizumab2 Second PD-L1/VEGF-A 11,2 NR
Legend: mTKI Multiple Tyrosine Kinase Inhibitor, VEGF-A Vascular Endotelial Growth Factor A, mTOR Mammalian Target of Rapamycin, PD-1 Programmed Death 1,
PD-L1 Programmed Death Ligand 1, NR Not Reached
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Conclusion
Clinical judgment remains of fundamental value in de-
termining which therapeutic option is indicated for each
patient. Considering results of surgical approach in sin-
gle centre studies many questions remain unsolved, in-
cluding indications for a possible complementary role of
surgery and target therapy and in which cases metastatic
dissemination is out of any possible surgical control. To
our knowledge, complete resection in RCC metastases
either pancreatic or extra pancreatic in fit patients, pro-
duce survival and QoL benefit when indolent growth
patterns are showed by primary malignancy.
A multidisciplinary approach is essential, considering
the patient as a whole in his/her individuality, with his/
her own needs and expectations, therefore periodical
QoL assessment and a lifelong follow-up are crucial in
order to achieve patient’s wellbeing either in surgical or
clinical settings. Patients with only Pancreatic Metastases
seems to show a better outcome than Extra-Pancreatic
Metastases’ patients, further and wider studies are neces-
sary to better determine differences in survival and nat-
ural history of the disease observed by this manuscript,
but prospective studies concerning this topic are difficult
to run, considering the rarity and long natural evolution
of the outlined disease.
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